Affimed (NASDAQ:AFMD) Sees Large Decrease in Short Interest

Affimed (NASDAQ:AFMD) was the recipient of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 611,400 shares, a decline of 39.5% from the November 15th total of 1,010,000 shares. Based on an average daily volume of 180,400 shares, the days-to-cover ratio is currently 3.4 days. Currently, 4.7% of the shares of the stock are short sold.

Affimed Stock Performance

Shares of AFMD opened at $2.15 on Friday. The business’s 50-day moving average is $3.08 and its 200-day moving average is $4.17. Affimed has a fifty-two week low of $2.02 and a fifty-two week high of $8.95. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13.

Institutional Investors Weigh In On Affimed

Institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC boosted its holdings in Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 4,086 shares during the period. Choreo LLC bought a new stake in Affimed in the 2nd quarter valued at $54,000. Intellectus Partners LLC raised its position in shares of Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 10,250 shares during the last quarter. Jane Street Group LLC bought a new position in Affimed during the third quarter valued at about $44,000. Finally, Point72 Asset Management L.P. grew its holdings in shares of Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after purchasing an additional 15,108 shares in the last quarter. Institutional investors and hedge funds own 30.82% of the company’s stock.

Wall Street Analyst Weigh In

AFMD has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th. Wells Fargo & Company dropped their price objective on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday. Stifel Nicolaus dropped their target price on Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Affimed in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $13.50.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.